140 related articles for article (PubMed ID: 34133478)
1. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis.
Mu LY; Li SQ; Tang LX; Li R
Clinics (Sao Paulo); 2021; 76():e2409. PubMed ID: 34133478
[TBL] [Abstract][Full Text] [Related]
2. Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials.
Jie Y; Youchun L; Jingxiang C
Afr Health Sci; 2023 Jun; 23(2):402-408. PubMed ID: 38223578
[TBL] [Abstract][Full Text] [Related]
3. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
[TBL] [Abstract][Full Text] [Related]
4. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis.
Weinberg EM; Curry MP; Frenette CT; Regenstein FG; Schiff ER; Goodman ZD; Robinson JM; Chan JL; Imperial JC; Reddy KR
Liver Transpl; 2021 Apr; 27(4):568-579. PubMed ID: 33164276
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
[TBL] [Abstract][Full Text] [Related]
9. A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.
Mehta G; Rousell S; Burgess G; Morris M; Wright G; McPherson S; Frenette C; Cave M; Hagerty DT; Spada A; Jalan R
J Clin Exp Hepatol; 2018 Sep; 8(3):224-234. PubMed ID: 30302038
[TBL] [Abstract][Full Text] [Related]
10. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Garcia-Tsao G; Fuchs M; Shiffman M; Borg BB; Pyrsopoulos N; Shetty K; Gallegos-Orozco JF; Reddy KR; Feyssa E; Chan JL; Yamashita M; Robinson JM; Spada AP; Hagerty DT; Bosch J
Hepatology; 2019 Feb; 69(2):717-728. PubMed ID: 30063802
[TBL] [Abstract][Full Text] [Related]
11. The impact of emricasan on chronic liver diseases: current data.
Lekakis V; Cholongitas E
Clin J Gastroenterol; 2022 Apr; 15(2):271-285. PubMed ID: 35000120
[TBL] [Abstract][Full Text] [Related]
12. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation.
Eguchi A; Koyama Y; Wree A; Johnson CD; Nakamura R; Povero D; Kneiber D; Tameda M; Contreras P; Spada A; Feldstein AE
J Mol Med (Berl); 2018 Jun; 96(6):575-583. PubMed ID: 29728708
[TBL] [Abstract][Full Text] [Related]
13. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
16. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
17. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
Saffioti F; Gurusamy KS; Eusebi LH; Tsochatzis E; Davidson BR; Thorburn D
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011648. PubMed ID: 28350426
[TBL] [Abstract][Full Text] [Related]
19. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
Castells X; Blanco-Silvente L; Cunill R
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
[TBL] [Abstract][Full Text] [Related]
20. Probiotics for people with cystic fibrosis.
Coffey MJ; Garg M; Homaira N; Jaffe A; Ooi CY
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012949. PubMed ID: 31962375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
